In an exciting development for the medicinal cannabis community, recruitment has now commenced for a world-leading clinical trial evaluating three pharmaceutical-grade medicinal cannabis oils for the treatment of chronic pain originating from musculoskeletal conditions. The study is spearheaded by respected Principal Investigator, Dr Matthew Moore MD FAAFP FACRRM EM Cert, and financially sponsored by Levin Health, an Australian sports science company.
About the Trial
Levin Health is focused on researching, developing, and commercialising medicinal cannabis products for pain treatment, mental health disorders, and sports-related ailments. This double-blind, placebo-controlled, randomised trial aims to examine the effectiveness of Levin Health’s licensed formulas in managing chronic musculoskeletal pain.
The study seeks to determine if there is an improvement in patient-reported outcome measures over a 12-week period while using a standardised oral formulation of medicinal cannabis (MC) oil. The trial will also monitor any adverse outcomes that might occur during the medication intake.
The trial’s design is a prospective, longitudinal observational study involving a defined population. The trial’s ultimate objective is to ascertain if this specific medication necessitates further and more rigorous clinical trial investigation as a potential treatment for chronic musculoskeletal pain.
The study’s unique approach will involve three distinct Levin Health products: Levin Health CBD+, Levin Health Balance, and Levin Health THC+. The choice of prescription for each participant will be at the clinical discretion of the Principal Investigator.
Participants will complete standardized and validated electronic Patient Reported Outcome Measures (PROMs) weekly using their home computers or devices. These measures will be compared to baseline measures taken at the beginning of the study.
Eligibility and How to Join
For more information, feel free to contact Sharlene Mavor at [email protected].
This trial is a significant step forward in our understanding of the potential benefits of medicinal cannabis in treating chronic pain, so don’t miss the opportunity to be part of this groundbreaking study.
Registration Number: ACTRN12622000750785
Source: Cannabis News. Licensed by Copyright Agency. You must not copy this work without permission. Designed to help you stay informed about the latest developments in the Australian medicinal cannabis landscape, this page includes curated articles covering key legislative changes, scientific research, and industry trends.